Mantziaris Vasileios, Kolios George
From the Department of Clinical Pharmacology and Therapeutics, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Crit Pathw Cardiol. 2019 Sep;18(3):139-142. doi: 10.1097/HPC.0000000000000187.
Several studies have gathered interest in the relationship between gut microbiota and atherosclerosis. Gut microbiota and its metabolites, such as trimethylamine-N-oxide, and gut dysbiosis play an important role in the development of atherosclerosis. Also, inflammation, derived by the intestinal tract, adds another mechanism through which the ecosystem of the human body affects the metabolic diseases and, furthermore, cardiovascular diseases. The scientific world should fixate the understanding of the exact physiologic and pathophysiologic mechanisms for atherogenesis by gut microbiota and through that, new ways for novel therapeutic targets will be available in the coming years. This review summarizes the latest data on this matter.
多项研究引发了人们对肠道微生物群与动脉粥样硬化之间关系的兴趣。肠道微生物群及其代谢产物，如氧化三甲胺，以及肠道生态失调在动脉粥样硬化的发展中起着重要作用。此外，源自肠道的炎症增加了另一种机制，通过该机制人体生态系统影响代谢性疾病，进而影响心血管疾病。科学界应专注于了解肠道微生物群引发动脉粥样硬化的确切生理和病理生理机制，通过这一点，未来几年将有新的方法用于确定新的治疗靶点。本综述总结了关于这一问题的最新数据。
